Vaccine Research and Development Center, National Health Research Institutes, Zhunan, Miaoli, Taiwan.
PLoS One. 2011;6(8):e23319. doi: 10.1371/journal.pone.0023319. Epub 2011 Aug 3.
To protect against dengue viral infection, a novel lipidated dengue subunit vaccine was rationally designed to contain the consensus amino acid sequences derived from four serotypes of dengue viruses. We found that the lipidated consensus dengue virus envelope protein domain III (LcED III) is capable of activating antigen-presenting cells and enhancing cellular and humoral immune responses. A single-dose of LcED III immunization in mice without extra adjuvant formulation is sufficient to elicit neutralizing antibodies against all four serotypes of dengue viruses. In addition, strong memory responses were elicited in mice immunized with a single-dose of LcED III. Quick, anamnestic neutralizing antibody responses to a live dengue virus challenge were elicited at week 28 post-immunization. These results demonstrate the promising possibility of a future successful tetravalent vaccine against dengue viral infections that utilizes one-dose vaccination with LcED III.
为了预防登革热病毒感染,我们设计了一种新型的脂化登革热亚单位疫苗,该疫苗包含来自四种登革热病毒血清型的保守氨基酸序列。我们发现,脂化的登革热病毒包膜蛋白结构域 III(LcED III)能够激活抗原呈递细胞,并增强细胞和体液免疫反应。在没有额外佐剂配方的情况下,单次给予小鼠 LcED III 免疫足以诱导针对所有四种登革热病毒血清型的中和抗体。此外,单次给予 LcED III 免疫的小鼠能够产生强烈的记忆反应。在免疫后 28 周,快速产生了针对活的登革热病毒挑战的记忆性中和抗体反应。这些结果表明,利用 LcED III 进行一剂接种的未来成功的四价登革热病毒疫苗具有很大的应用前景。